Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Dengue Fever Vaccine
Dengue type-2 vaccine candidates evaluated in rhesus macaque model
September 14th, 2005
Scientists evaluate dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model in a recent issue of the journal Vaccine. "The safety, immunogenicity, and protective efficacy of two non-replicating antigen-based vaccines and one live-attenuated virus (LAV) vaccine for dengue type-2 (dengue-2) virus were evaluated in the rhesus macaque model. The non-replicating vaccines consisted of whole, purified inactivated virus (PIV) and a recombinant subunit protein containing the amino-(N)-terminal 80% of envelope protein (r80E), each formulated with one of five different adjuvants," scientists in the United States and...
Source: Vaccine Weekly (2005-09-14)
|
